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eng.yu@csu.edu.cnAbstract A sensitive and reliable method based on liquid chromatography tandem mass spectro-
metry (LC–MS/MS) for the quantitation of cyclovirobuxine D in human plasma has been
developed and validated. Sample preparation by solid phase extraction was followed by separation
on a CN column with a mobile phase of methanol–water (95:5, v/v) containing 0.2% formic acid.
Mass spectrometric detection in the positive ion mode was carried out by selected reaction
monitoring (SRM) of the transitions at m/z 403.0-372.0 for cyclovirobuxine D and m/z 325.0-
234.0 for citalopram (internal standard). The method was linear in the range 10–200 ng/L with
LLOQ of 10 ng/L, recovery 485%, and no signiﬁcant matrix effects. Intra- and inter-day
precisions were all o9% with accuracies of 94.0–104.8%. The method was successfully applied
to a pharmacokinetic study involving a single oral administration of a 2 mg cyclovirobuxine D
tablet to twenty-two healthy Chinese volunteers.
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Cyclovirobuxine D in human plasma by liquid chromatography tandem mass spectrometry 1851. Introduction
Cyclovirobuxine D (CVB-D; Fig. 1) is a steroidal alkaloid
extracted from the plant Buxux microphylla. It is widely used
in China for the treatment of cardiac insufﬁciency, angina
pectoris and arrhythmias1. CVB-D can signiﬁcantly increase
the viability of cardiomyocytes injured by oxidation or
hypoxia via cytoprotection, opening KATP channels, stimulat-
ing NO release and inhibiting venous thrombosis2.
CVB-D is orally active and requires a daily dose of only
2 mg for adults. This low dose leads to a very low concentra-
tion of CVB-D in body ﬂuids making it difﬁcult to carry out
therapeutic drug monitoring (TDM) or pharmacokinetic
studies. In fact, only a few methods for the determination of
CVB-D in human body ﬂuids have been reported despite the
fact that CVB-D has been in clinical use for over twenty years.
Recently Yu et al.3 developed an analytical method
based on liquid chromatography tandem mass spectrometry
(LC–MS/MS) with electrospray ionization (ESI) and applied
it to a pharmacokinetic study in healthy volunteers given 2 mg
CVB-D by venous infusion. Despite a lower limit of quantita-
tion (LLOQ) of 200 ng/L3, the method remained unsuitable
for the pharmacokinetic study because the Cmax of CVB-D
was o200 ng/L. In the same year, Ding et al.4 reported an
LC–MS method using atmospheric pressure chemical ioniza-
tion (APCI) in which an LLOQ of 10.1 ng/L was claimed.
Unfortunately the assay was performed on a single-quadru-
pole mass spectrometer with a highly aqueous mobile phase
making the sensitivity and selectivity of the method rather
doubtful. In addition, matrix effects were not evaluated and
concentrations of CVB-D in all samples were within the lower
1/30 of the linear range. Moreover, both these methods
involved liquid–liquid extraction (LLE) from basiﬁed samples,
which resulted in signiﬁcant adsorption of CVB-D onto
glassware.
In order to establish a sensitive and reliable method for
TDM and pharmacokinetic studies of CVB-D after oral
administration of therapeutic doses, we have developed and
validated a novel method based on sample preparation by
solid phase extraction (SPE) followed by LC–APCI–MS/MS.
The method overcomes the shortcomings of previous assays
and has been successfully applied to a pharmacokinetic study
of CVB-D tablets in healthy Chinese volunteers.Figure 1 The chemical structure of CVB-D.2. Materials and method
2.1. Materials
The CVB-D reference standard (batch number: 110888-
200202, purity: 97.6%) was obtained from the National
Institute for the Control of Pharmaceutical and Biological
Products (Beijing, China). Citalopram, for use as internal
standard (IS), was purchased from Sigma-Aldrich (St. Louis,
USA). CVB-D tablets (1 mg formation) were provided by
Tianjin LB Bioengineering Co., Ltd. (Tianjin, China). Deio-
nized water was processed through a Milli-Q water puriﬁca-
tion system (Millipore, Milford, USA). Methanol was HPLC
grade from Merck, Darmstadt, Germany. SPE columns
(StrataTM-X 8B-S100-TAK) were purchased from Phenom-
enex (Torrance, USA) and mounted on a VacElut vacuum
manifold (Supleco, Bellefonte, USA). Blank human plasma
was obtained from the Nanjing Red Cross Blood Center
(Nanjing, China). All other chemicals were of analytical grade
and used as received.2.2. Preparation of calibration standards and quality control
samples
A CVB-D stock solution (100 mg/L) was prepared in metha-
nol containing 0.2% formic acid and stored at 4 1C when not
in use. Standard solutions were made by dilution of the stock
solution with methanol containing 0.2% formic acid. Aliquots
(20 mL) of these standard solutions were used to spike 0.5 mL
aliquots of blank human plasma to give calibration standards
with concentrations of 0, 10, 20, 40, 75, 125 and 200 ng/L.
Quality control (QC) samples (20, 75 and 150 ng/L) were
prepared in the same way from an independently prepared
stock solution. A working IS solution (200 ng/mL) in metha-
nol was also prepared.2.3. Sample preparation
Prior to SPE, frozen plasma samples were thawed in a water
bath at 37 1C. SPE columns were activated by elution with
1 mL methanol followed by 1 mL water. Plasma samples
(0.5 mL) were mixed with 0.5 mL of 20 mmol/L acetate buffer
(pH 5.2) and 20 mL IS working solution and loaded onto
activated SPE columns. After elution at 1 mL/min under
reduced pressure, columns were washed with 1 mL water
followed by 1 mL 25% methanol and dried under reduced
pressure for 3 min. Finally, the analyte was eluted with 1 mL
methanol containing 1% formic acid, and the eluent evapo-
rated to dryness under a gentle stream of nitrogen at 60 1C.
Dried extracts were reconstituted in 100 mL mobile phase and
10-mL aliquots injected into the LC–MS system.2.4. LC–MS/MS conditions
Analysis was performed on a Finnigan TSQ LC–MS/MS
system (Thermo Electron Corporation, San Jose, USA) con-
sisting of a Finnigan Surveyor LC pump, a Finnigan Surveyor
refrigerated autosampler, and a Finnigan TSQ Quantum
Ultra AM triple quadrupole tandem mass spectrometer
with an APCI interface and a two-port diverter valve. The
Ling-li Mu et al.186LC–MS/MS system was operated under Xcaliburs 1.1 soft-
ware at ambient temperature (2572 1C).
Chromatography was performed on a Phenomenex CN
column (5 mm, 150 mm 2.1 mm i.d., Torrance, USA) pro-
tected by 4.0 mm 2.0 mm i.d. Phenomenex CN guard column.
The isocratic mobile phase was methanol–water (95:5, v/v)Figure 2 Representative chromatograms obtained from human plasm
CVB-D at 20 ng/L and citalopram (IS) at 40 ng/L; (c) a clinical sampcontaining 0.2% formic acid at a ﬂow rate of 0.25 mL/min. The
eluate was directed to waste for the ﬁrst 2.8 min and then to the
mass spectrometer using a diverter valve.
The APCI source was operated in the positive ion mode and
optimized by constant infusion of a CVB-D standard solution
(500 mg/L) in mobile phase into the HPLC ﬂow using a syringea samples: (a) blank human plasma; (b) plasma sample spiked with
le.
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selected reaction monitoring (SRM) mode using the transi-
tions at m/z 403.0-372.0 for CVB-D and m/z 325.0-234.0
for IS. Optimum APCI–MS/MS parameters were as follows:
discharge current 18 mA; APCI vaporizer temperature 400 1C;
sheath gas (N2) pressure 35 psi; auxiliary gas (N2) pressure
5 psi; capillary temperature 300 1C; source CID 10 V; collision
energy 25 V; collision gas (Ar) pressure 1.5 mTorr.
2.5. Assay validation
Speciﬁcity was assessed by analysis of plasma samples from six
individual donors. Linearity was tested by linear regression of
calibration curves based on peak area ratios of analyte to IS.
Evaluation of precision and accuracy involved analysis of ﬁve
replicates of QC samples on three separate occasions. Recov-
ery was determined by comparing peak areas of QC samples
prior to extraction with those of plasma samples spiked post-
extraction. Matrix effects were evaluated at 20, 75 and 150 ng/L
for analyte by comparing the peak areas of samples (n¼5)
spiked post-extraction with those of standard solutions at the
same concentration.
Stability of CVB-D was evaluated by assay in triplicate of
QC samples under the following conditions: At ambient
temperature over 12 h (short-term stability); at 20 1C for
over 30 days (long-term stability); and after three freeze–thaw
cycles (room temperature to 20 1C) (freeze–thaw stability).
Post-preparative stability was also evaluated under autosam-
pler conditions (10 1C) for over 24 h.
2.6. Pharmacokinetic study
A pharmacokinetic study in twenty-two healthy Chinese male
volunteers was performed according to the Declaration of
Helsinki for Biomedical Research involving human subjects
and the rules of good clinical practice (GCP). All volunteers
gave written informed consent before entering the study.
Venous blood samples (5 mL) were collected into heparinized
tubes before the dose and at 5, 15, 30, 45 min, 1, 2, 4, 10, 16,
24, 36, 48, 72, 96, 120 h after administration of a single oral
dose of 2 mg CVB-D tablets, respectively. Blood samples were
immediately centrifuged and plasma frozen at 20 1C until
analysis. Pharmacokinetic parameters of CVB-D, including
maximum plasma concentration (Cmax), time to Cmax (Tmax),
area under the plasma concentration–time curve from time
zero to the last measurable concentration (AUC0–t), area
under the plasma concentration–time curve from time zero
to inﬁnity (AUC0–N) and elimination half-life (t1/2), were
calculated using DAS Ver 2.0 software.3. Results and discussion
3.1. LC–MS conditions
Assay development in this study was based on previously
reported methods3,4. Thus chromatography was performed on
a CN analytical column using a mobile phase containing a
high percentage of organic solvent as described by Yu et al.3
This provided good ionization efﬁciency and elimination of
ion suppression. An APCI source was employed as in thestudy by Ding et al.4 since it provided a more stable response
than an ESI source. These features together with detection by
MS/MS gave an LLOQ of 10 ng/L with good precision and
accuracy. This sensitivity was suitable for TDM and for
clinical pharmacokinetic studies.
3.2. Assay validation
3.2.1. Speciﬁcity
Representative chromatograms of blank and spiked human
plasma samples are shown in Fig. 2. The mean retention times
for CVB-D and IS were 4.9 and 3.3 min, respectively, with an
overall chromatographic run time of 6 min. All plasma samples
were free of interference at the retention times of both CVB-D
and IS.
3.2.2. Linearity and LLOQ
The calibration curve was linear in the range 10–200 ng/L with
r40.99. The LLOQ (deﬁned as the lowest amount of analyte
that can be quantitatively determined with suitable precision
and accuracy5) was shown to be 10 ng/L on the basis of intra-
and inter-day precision values of 6.27% and 5.73%, respec-
tively, and corresponding accuracy values of 104.8% and
98.3%, respectively.
3.2.3. Precision and accuracy
Intra- and inter-day precision and accuracy results are sum-
marized in Table 1. As shown, precision at all concentrations
was o9% with accuracy in the range 94.0–104.8%. All values
were within the limits recommended for bioanalytical method
validation5.
3.2.4. Sample preparation
CVB-D is a basic steroidal alkaloid, which has a tendency to
adsorb to glassware under alkaline conditions6. In previous
methods, samples have been strongly basiﬁed and subjected to
liquid–liquid extraction (LLE) with organic solvents3,4,7. In
order to reduce the uncertainty caused by adsorption, it was
decided to avoid LLE and use SPE instead. After initial
screening of SPE sorbents, StrataTM-X columns were chosen
because, unlike silica-based reversed phase columns, they are
known to retain moderately polar compounds whilst allowing
efﬁcient washing to remove contaminants. In this study they
produced clean extracts with high recovery of CVB-D. In fact,
the extraction recoveries at concentrations of 20, 75 and
150 ng/L were 91.2%, 94.0% and 95.5%, respectively. Recov-
ery of the internal standard was 94.8%.
3.2.5. Matrix effects
In terms of matrix effects, concentrations of samples contain-
ing 20, 75 and 150 ng/mL CVB-D were found to be 104.4%,
102.2% and 106.2% of the nominal concentrations, respec-
tively. This indicates that matrix effects are not an issue using
the current method8.
3.2.6. Stability
In terms of stability, the results shown in Table 2 show that
CVB-D is stable in human plasma and in processed samples
under the conditions described.
Table 1 Intra- and inter-day precision and accuracy for assay of CVB-D in human plasma.
Nominal
concentration
(ng/L)
Intra-day (n¼5) Inter-day (n¼15)
Determined mean
concentration (ng/L)
RSD (%) Mean
accuracy
(%)
Determined mean
concentration (ng/L)
RSD (%) Mean accuracy
(%)
20 20.96 6.27 104.8 19.66 5.73 98.3
75 70.52 8.98 94.0 71.81 6.73 95.7
150 149.5 8.10 99.7 142.6 4.23 95.1
Table 2 Stability of CVB-D in human plasma (n¼3).
Item 20 ng/L 75 ng/L 150 ng/L
Determined
mean
concentration
RSD
(%)
Mean
accuracy
(%)
Determined
mean
concentration
RSD
(%)
Mean
accuracy
(%)
Determined
mean
concentration
RSD
(%)
Mean
accuracy
(%)
Short-term stability 20.28 5.23 101.4 70.84 6.19 94.4 137.2 4.85 91.5
Freeze–thaw stability 18.00 7.96 90.0 64.63 5.84 86.2 155.3 6.61 103.6
Long-term stability 19.16 7.03 95.8 69.88 7.70 93.2 153.0 6.52 102.0
Post-preparative
stability
17.40 8.54 87.0 65.32 6.98 87.1 161.8 8.47 107.9
Figure 3 Mean plasma concentration–time proﬁle over 120 h of
CVB-D in twenty-two subjects each receiving a single oral dose of
a CVB-D 2 mg tablet. Each point represents mean7SD (n¼22).
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The present method was successfully applied to a pharmacoki-
netic study involving twenty-two healthy Chinese male volun-
teers after oral administration of a single dose of 2 mg CVB-D
tablets. The mean plasma concentration versus time proﬁle of
CVB-D is shown in Fig. 3 and corresponding pharmacokinetic
parameters are as follows: Cmax, 121755 ng/L; Tmax, 1077 h;
t1/2, 39714 h; AUC0–120, 439871656 ng  h/L; AUC0–N,
529272034 ng  h/L.5. Conclusions
A novel LC–APCI–MS/MS method for the determination of
CVB-D in human plasma has been developed and validated.
The main advantages of the method include simple samplepreparation by solid phase extraction and high sensitivity.
This method is suitable for clinical pharmacokinetic studies as
shown by its successful application in a pharmacokinetic study
of CVB-D 2 mg tablets in healthy Chinese male volunteers.References
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